Parkinsons Disease: Positive opinion by the CHMP issued recommending the granting of a marketing authorisation for Safinamide (Xadago)
Last Updated on March 18, 2018 by Joseph Gut – thasso
On 18 December 2014, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Xadago, 50 mg and 100 mg, film-coated tablet intended for the treatment of Parkinson’s disease. The active substance of Xadago is safinamide, a highly selective and reversible MAO-B inhibitor causing an increase in extracellular levels of dopamine in the striatum. Xadago is also associated with state-dependent inhibition of voltage-gated sodium (Na+) channels, and modulation of stimulated release of glutamate.
The benefits with Xadago are its ability to improve the ON time in patients with motor fluctuations, currently receiving L-dopa alone or in combination with other PD medications. The most common side effects are dyskinesia, somnolence, dizziness, headache, insomnia, nausea and orthostatic hypotension. A pharmacovigilance plan for Xadago will be implemented as part of the marketing authorisation. The approved indication is: “Xadago is indicated for the treatment of adult patients with idiopathic Parkinson’s disease (PD) as add-on therapy to a stable dose of Levodopa (L-dopa) alone or in combination with other PD medicinal products in mid-to late-stage fluctuating patients.”
Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the upcoming European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.
The CHMP, on the basis of quality, safety and efficacy data submitted, considers there to be a favourable benefit-to-risk balance for Xadago and therefore recommends the granting of the marketing authorisation.
Related posts
Unlucky women with BIA-ALCL: An update
Sodium-glucose cotransporter-2 (SGLT2) inhibitors in Type-2 Diabetes: Risk of ac...
Diabetes: No end to SGLT2-inhibitor drugs side effects
Genetic variants in extremely ill COVID patients explain how fatally sick people...
Immunemodulation: Cancer drug trial halted after three test subjects die
Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.
I was recommended this website by my cousin. I am not
sure whether this post is written by him as nobody else know such detailed about my
problem. You are incredible! Thanks!
Descargar facebook
Sweet blog! I found it while searching on Yahoo News.
Do you have any tips on how to get listed in Yahoo News?
I’ve been trying for a while but I never seem to get there!
Thanks descargar facebook
This is a really good tip particularly to those new to the blogosphere.
Brief but very precise info… Appreciate your sharing this one.
A must read article!
Heya i am for the first time here. I found this board and I find It truly useful & it helped me out a
lot. I hope to give something back and aid others like you aided me.
whoah this blog is fantastic i really like reading your articles.
Keep up the good work! You already know, many persons are searching round for this
information, you could aid them greatly.
Genuinely no matter if someone doesn’t understand
afterward its up to other people that they will
help, so here it occurs.
So ice creams, cookies, deep frozen meals is no
way allow. So I recommend that you start out with walking and jogging to
start with, combined with easy ab workouts, like sit-ups.
Sleep deprivation can be linked to several health issues,
including heart problems.
At this moment I am going away to do my breakfast, once having my breakfast coming over again to read more
news.